Last reviewed · How we verify

NCT05415774: SCP-FOG

Combined Deep Brain Stimulation in Parkinson's Disease

Completed NA Last updated 28 November 2025
What this trial tests

NA trial testing 1 : S-C1-C2 in Parkinson Disease in 10 participants. Completed in 10 May 2023.

Timeline
9 September 2022
Primary endpoint
10 May 2023
10 May 2023

Quick facts

Lead sponsorUniversity Hospital, Toulouse
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposeother
Enrollment10
Start date9 September 2022
Primary completion10 May 2023
Estimated completion10 May 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

Adults 18 to 100, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a pilot study on Parkinson's disease patients to evaluate Combined deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus for unresponsive freezing of gait.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05415774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing